• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Phase Forward Revenue, Profits Jump

Phase Forward Revenue, Profits Jump

July 25, 2007
CenterWatch Staff

Waltham, Mass.-based Phase Forward, a provider of electronic data capture (EDC), drug safety and data management solutions for clinical trials, reported second quarter revenues rose 28% to $31.5 million and profits doubled.

At mid-day, Phase Forward's shares were up 11% to $18.18.

For the second quarter, income from operations increased 89% from the prior year period to $4.5 million, resulting in a 14.4% operating margin. Net income for the period was $5.6 million, or $0.14 per diluted share, compared with $2.7 million, or $0.07 per diluted share, in the second quarter of 2006.

License, application hosting and other related revenues increased 39% to $22.8 million from $16.3 million in the prior year period, representing 72% of second quarter 2007 total revenues.

"We are pleased with the company's performance during the second quarter, which was highlighted by major customer wins, new and expanded partnerships with contract research organizations (CROs), a breakthrough technology introduction and an increase in the level of competitive replacement activity. We continue to be encouraged by the overall strength of market demand for EDC and safety solutions, which is reflected in our increased outlook for bookings in 2007," said Bob Weiler, chief executive officer and president of Phase Forward.

During the second quarter, a top 10 pharmaceutical company expanded its adoption of Phase Forward’s EDC solution into a multi-year, multi-million dollar application services provider commitment.

“We believe the increasing adoption of EDC by the world's largest pharmaceutical companies adds further pressure on other companies to make similar investments or risk being at a competitive disadvantage. Phase Forward is benefiting from this trend due to our customer reference ability, proven scalability, global service and support infrastructure, as well as the breadth and depth of our products' functionality. In addition, our recently introduced Central Designer(TM) application can help customers shorten the EDC study design and build process more effectively, improving operational efficiencies and reducing the barriers to adoption for customers of all sizes," Weiler added.

Upcoming Events

  • 15Apr

    Five Telltale Signs You’re Ready for an Electronic TMF System

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

  • 06May

    The World of Post-COVID-19 Clinical Trials: How to Prepare for What’s Coming Next

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • Clinical-Trial-Brainstorming

    FDA, Industry Tackle Problem of Including Older Adults in Trials

  • ClinicalTrialNetwork-360x240.png

    National Community-Based Research Network Would Improve Reach of Trials

  • Bottleneck-360x240.png

    Sites Face Trials Bottleneck After Pandemic, But Also Opportunities

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Genetic Research and IBC Oversight Requirements

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing